Full-Time

Senior Platform Developer

Salesforce

Posted on 4/4/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (1)
Required Skills
Agile
Salesforce
AWS
DevOps
Google Analytics
Requirements
  • Master’s degree and 2 to 4 years of Computer Science, Information Technology or related field experience OR Bachelor’s degree and 5 to 6 years of Computer Science, Information Technology or related field experience OR Diploma and 7 to 9 years of Computer Science, Information Technology or related field experience
  • Advanced Salesforce development expertise including Apex, Visualforce, Lightning Web Components
  • Hands-on technical experience in delivering digital projects in a fast-paced, multi-client environment, including full design-build project lifecycle of web projects
  • Experience leading web and cloud technology systems: Salesforce Communities, AWS, Google Analytics, MuleSoft, etc
  • Knowledgeable of web analytics, search engine optimization principles and web design standard processes, code review, quality checks, and implementing best practices and compliance
  • Proficient in developing and supporting solutions within regulated GxP and CSV-compliant computer systems, ensuring adherence to validation, audit, and documentation standards
  • Ability to conduct the role in accordance to GxP and CSV regulations and requirements
Responsibilities
  • Act as the primary technical expert and point of contact for all Salesforce development activities across Medical Information Websites
  • Lead the implementation of new features and enhancements on Salesforce Experience Cloud, ensuring alignment with product roadmaps and user experience goals
  • Own critical development items and work closely with the team to ensure continuity and timely resolution of high-priority items
  • Maintain, monitor, and support production and non-production Salesforce environments
  • Handle and coordinate all aspects of the release process using Copado, including pipeline configuration, code integration, version control, deployment planning, and post-release validation
  • Use Copado’s continuous integration and delivery capabilities to streamline deployments, maintain environment consistency, and ensure traceability
  • Manage and coordinate all aspects of the release process, including code integration, sandbox refreshes, deployment planning, and post-release support
  • Ensure timely and high-quality delivery of technical solutions, following Amgen's agile development processes and industry standard methodologies
  • Maintain up-to-date technical documentation including design and build specifications, configuration logs, and deployment artifacts for audit and compliance purposes
  • Perform code reviews to ensure adherence to security, scalability, accessibility, performance standards and compliance with Vera validation standards
  • Collaborate with cybersecurity teams to implement security protocols, ensure platform security posture, respond to vulnerabilities and audit findings and alignment with Amgen’s governance, security, and compliance frameworks
  • Deploy and validate code in development and QA environments using Copado pipelines and automated testing workflows
  • Support the maintenance of integrations between Salesforce and other platforms such as AWS, MuleSoft, and other third-party services.
  • Provide technical mentorship to junior developers and contribute to knowledge-sharing sessions within the development team
  • Ensure platform compliance with GxP, GDPR, and other regulatory requirements specific to the pharmaceutical industry
  • Drive the adoption of DevOps practices by supporting continuous integration, automated testing, and deployment pipelines
  • Collaborate with multi-functional teams to solve, optimize, and continuously improve platform functionality
  • Participate actively in PI Planning, Sprint Planning, and other SAFe Agile ceremonies to ensure full visibility and accountability across deliverables
  • Uphold platform scalability, reusability, and future-readiness by recommending standard methodologies and reusable frameworks
  • Ability to conduct the role in accordance to GxP and CSV regulations and requirements
Desired Qualifications
  • Salesforce Administrator or App Builder (preferred)
  • SAFe Agile Certification (preferred)
  • Experience with Salesforce DevOps Center or other DevOps pipelines
  • Knowledge of AWS, MuleSoft, web services, and REST/SOAP APIs
  • Familiarity with Jira, Confluence, and agile development tracking tools
  • Knowledge of front-end technologies (HTML, CSS, JavaScript)
  • Experience in the validation process for GxP-regulated systems, including understanding of system lifecycle and compliance requirements
  • Experience working with geographically dispersed teams in a matrix environment
  • Understanding of web accessibility and responsive design
  • Experience operating in a regulated business environment and adhering to mandatory compliance requirements preferred
  • Pharmaceutical experience preferred
  • Professional Certifications: Salesforce Platform Developer I & II (must have)
  • Salesforce Platform Developer I & II (must have)
  • Salesforce Administrator or App Builder (preferred)
  • SAFe Agile Certification (preferred)
  • Soft Skills:
  • Effective collaboration in cross-functional and distributed teams
  • Strong initiative and self-drive in a dynamic environment
  • Excellent problem-solving and debugging skills
  • Standout colleague with a collaborative attitude
  • Experience working in Agile/Scrum teams
  • Ability to collaborate with QA, compliance, validation, and security teams
  • Ability to handle and prioritize numerous tasks effectively
  • High attention to detail and commitment to quality
  • Willingness to mentor junior developers and share best practices
  • Adaptability to work in a fast-paced, evolving technical landscape
  • Pharmaceutical experience preferred

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE